S&P 500
7,226.20
+0.01%
Dow Jones
49,494.60
-0.62%
Nasdaq 100
27,685.40
+0.66%
Russell 2000
2,804.78
-0.02%
FTSE 100
10,364.50
0.00%
Nikkei 225
59,260.50
-0.78%

Health and Healthcare

7 Biotechs With Catalysts in the Next Month

Photo of Chris Lange
By Chris Lange Updated Published
Follow 24/7 Wall St. on Google
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
7 Biotechs With Catalysts in the Next Month

© Eva-Katalin / Getty Images

[cnxvideo id=”751956″ placement=”prodege”]
If there is one area that can generate riches for speculative investors, it would have to be biotech and emerging pharmaceuticals. After all, how many companies can go from nothing to billions in sales so quickly? Savvy investors are also well aware that these companies can turn a large fortune into a small one for those speculative investors who make the wrong moves.

In simpler terms, these updates within the industry have the potential to make or break biopharma companies.

Here, 24/7 Wall St. includes a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the rest of September and in October.

NovoCure Ltd. (NASDAQ: NVCR) has multiple presentations in tumor treating fields scheduled for September 15 to 18 at the American Society for Radiation Oncology meeting in Chicago.

Kiniksa Pharmaceuticals Ltd. (NASDAQ: KNSA) will present preclinical data of oncostatin M receptor beta expression in chronic pruritic diseases at the European Society for Dermatological Research annual meeting in France. The meeting is scheduled on for September 18 to 21.

Turning Point Therapeutics Inc. (NASDAQ: TPTX) is releasing updated Phase 1 Trident-1 data and preclinical TPX-0046 data at the European Society for Medical Oncology (ESMO) on September 28.

G1 Therapeutics Inc. (NASDAQ: GTHX) has an investor event scheduled at the ESMO on September 29. At this time, the firm will report preliminary G1T48 Phase 1 data, lerociclib dose escalation data in non-small cell lung cancer and trilaciclib Phase 2 data in small cell lung cancer.

Audentes Therapeutics Inc. (NASDAQ: BOLD) will release an update on Aspiro at the International Annual Congress of the World Muscle Society on October 1 to 5 in Denmark. The Aspiro trial is exploring a treatment for X-linked myotubular myopathy.

ObsEva S.A. (NASDAQ: OBSV) is releasing full safety data from its Implant 2 study at the 75th American Society for Reproductive Medicine in Philadelphia. This data will be presented on October 12 to 16.

Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) has a Prescription Drug User Fee Act (PDUFA) for Ultomiris scheduled for October 19. Ultomiris is a treatment option for adult patients living with paroxysmal nocturnal hemoglobinuria.

[recirclink id=576771]
[wallst_email_signup]

Photo of Chris Lange
About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Half of America Still Feels Financially Exposed Despite 8% Jump in Security
David Beren |

Half of America Still Feels Financially Exposed Despite 8% Jump in Security
52% of Americans Are Building Wealth While Ignoring Their Greatest Risk
David Beren |

52% of Americans Are Building Wealth While Ignoring Their Greatest Risk

Continue Reading

7 Biotechs With Catalysts in the Next Month
Chris Lange |

7 Biotechs With Catalysts in the Next Month

Here, 24/7 Wall St. includes a calendar of a few of the biggest companies expecting clinical trial and FDA updates…
Major Biopharma Catalysts to Watch For in October
Chris Lange |

Major Biopharma Catalysts to Watch For in October

Here 24/7 Wall St. includes a calendar of a few of the biggest companies expecting clinical trial and FDA updates…
Key FDA Decisions and Trial Results Coming in the Next 2 Months
Chris Lange |

Key FDA Decisions and Trial Results Coming in the Next 2 Months

24/7 Wall St. has collected several big FDA decisions and mid- to late-stage trials that should be coming up in…
Major Biopharma Catalysts on October’s FDA Calendar
Chris Lange |

Major Biopharma Catalysts on October’s FDA Calendar

Here is a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the month…
Key FDA Decisions and Trial Results Expected in October
Chris Lange |

Key FDA Decisions and Trial Results Expected in October

24/7 Wall St. has collected several big FDA decisions and mid-to-late-stage trials that should be coming up in October. These…
What Wedbush Sees Coming in ASCO’s 2020 Annual Meeting
Chris Lange |

What Wedbush Sees Coming in ASCO’s 2020 Annual Meeting

Wedbush took a closer look at some of the companies in its coverage universe that are set to present at…
Even More Biopharma and FDA Catalysts Coming in October
Chris Lange |

Even More Biopharma and FDA Catalysts Coming in October

24/7 Wall St. has collected a few more catalysts that are coming up in October for biotech and pharmaceutical companies.
Jon C. Ogg |

An Early Look at 2012 ASCO Biotech Cancer Stocks (DNDN, LLY, AMGN, ARIA, ARQL, ARRY, AVEO, BVTI, ABPI, BMY, CLDX, CYTR, CYCC, GALE, EXEL, GNBT, GHDX, IMGN, MYGN, NKTR, NLNK, ONXX, OPTR, PCYC, SGEN, SNSS, SNTA)

We are now just about two weeks away from the king of biotech and pharma events in cancer treatments.  The 2012…
Key FDA Decisions and Trial Results Expected in October
Chris Lange |

Key FDA Decisions and Trial Results Expected in October

24/7 Wall St. has collected several big FDA decisions and mid-stage to late-stage trials that should be announced in October.

Top Gaining Stocks

Cboe Global Markets
CBOE • Vol: 1,568,143
New Pluto Global
PSKY • Vol: 12,285,993
Seagate Technology
STX • Vol: 7,378,346
Oracle
ORCL • Vol: 26,317,675
Datadog
DDOG • Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ • Vol: 4,367,433
Clorox
CLX • Vol: 13,260,523
Stryker
SYK • Vol: 4,519,455
Mohawk Industries
MHK • Vol: 1,859,865
Amgen
AMGN • Vol: 3,818,618